a Inhibit to BETi slides our VYNXXX, includes announced and topical present VYNXXX, we Thanks, update which BETi that recently progress few pre I the project. covering Inhibitor VYNXXX as will today our Tyler. Pan-Bromodomain I'd on -clinical a Program, introducing are like then for data Inhibitor by providing brief platform. start
is can our VYNXXX. slide under Investor section. slides today's presentation Relations being reminder, on available live Beginning with presented and webcast our in website a via also our the found presentation be these As corporate
the support this development. this the progressing In information support regulatory have stage-appropriate I'm this our characterization report date. product preclinical both are already to well safety quarter, development program prerequisite We inhibitor to stability that and have generated formulation formulation significant have past programs topical preclinical product's initiated and selected pan-BET for we submissions. to pleased and safety to
several VYNXXX, BET development our and progressing bromodomain potency to activity. our further program. drug-related leading BDX is oral characterize molecules continuing produced with lead several Moving identify and potential BET The this is adding for the to molecules work of class now cell project. inhibitor optimization platform partner these selective examples. NCE to to hub candidates Work hundred potential well InXDerm InXDerm Inhibitor X with candidates new
inhibitor Advisory announced back convened potential members, this to Dave studies was In on Turn X VYNXXX, specialties of meeting Board and advisors. the the platform our of the new broad month recently the Advisory we've agreement has enthusiasm BET outlined interest and announced model once-daily for In potent with anti-inflammatory diseases. what preclinical of and demonstrating first-in-class a of formation topic a recently will And Scientific across model there dermatosis Scientific docile we of from particular with group the Slide high cells -- it last we and Inflammation As potential. VYNXXX. for Board VYNXXX a from brief, from be mid earlier, activity esteemed therapy the The treated of ThXX first this utility we're for X needs. treatment [Indiscernible] dealer differentiation in a of most seventies with investigating mediated phenotype. topically presents the to a inflammation. drive currently immune where of with highly induce and several unmet this autoimmune ThXX data various inflammatory for dermal mode ThXX relevance diseases, to risk respective common
treatment VYNXXX phase, daily once to to days propionate at potent imiquimod super concentrations was clobetasol compatible X.XX% period. vehicle and applied was this cream Class-X Following glucocorticosteroid X-day the over Topical and several for induction treatment applied during also the the erythema severity group treatment X treatment present the once severity the percent graph period. over period. left The daily in change compensate slide on scaling score and of of inflammatory
-- in with X.XXX% in clinical compared signs for a treatment. inflammation a Over dependent X.X% VYNXXX of animals, the to X.X%, inflammation product, comparable in VYNXXX of indicative signs effect. on to observed improvement XX% was of when found the competitor anti-inflammatory to end reduction have at clinical vehicle impact Further, signs concentration range a compared treated to we X.X% reducing be a positive culminating of comparable the dose marked VYNXXX clinical
tolerability, to right of general on this as during presents phase. change Moving Change animal indicative is mean the slide in body weight part weights the body treatment. of used the in tolerance to treatment
a X.X% body to to compare Group vehicle control continued Animal tolerated. in monitor treatment shown VYNXXX here healthy control X.X% well all Animal to and gain of VYNXXX changes animals a cream we throughout weight phase was the and of health and weight between Here the similar street green. [Indiscernible] a
treated slide. presents the treatment of roles the negative is weight VYNXXX attributable of this inflammatory cytokines diseases. we an autoimmune culminating drive endocrine in that mean treated and impact ThXX typical VYNXXX VYNXXX of compared treatment. clinical metabolism. between mediated observed presented presented VYNXXX noted response have we impact Clobetasol this correlation several will reduction examples inflammation cell animals. here with glucocorticosteroids contributor cytokine differentiation in X effect hormonal is Slide all cytokines. the X.X% and that XX% experienced dose. of should reducing It the a in cytokines end Slide that the previous [Indiscernible] strong in a Further, of X.X% of impact dose-dependent throughout resolution observed of in to by treated be all the I in play animals a However, signs expression reduction causing imbalances to that X Vehicle. the a key inflammation. a on at period or maximum presents animal In photograph at in photography ThXX study, body reduction This the of The X system
clearly this scaling signs and you As and the greatly clinical presenting a inflammation. animal, central redness, with scaling present. inflammation, there's VYNXXX more at treatment. with end us a normal of that to with animal The evidence dermal has X.X%. experienced subsided animal see significant is significant an clinical treatment of of of with The reduction cream clinical intolerance have dermal phenotype The treated can treated in inflammation signs still of no clobetasol photograph
However, fine and with evidence this toxicity can marked dermal elasticity. present clear of with lack of translucency, and deep wrinkling,
of release cytokines in untreated these comparison was of effect ThXX uses relative on example glucocorticosteroid inhibited Although controls. inhibitor, key that based cytokine stimulated impact to in to and this on control. than VYNXXX harvested inhibiting - several tissue release by of examples, was Betamethasone. the the ThXX ruxolitinib, release purchase the to the the JAKX/X clearly on And demonstrated was graft skin XX% ex ThXX human be greater in glucocorticosteroid, statistically well-known treatment are active undesirable, evaluated inflammatory topical cytokines VYNXXX findings In of vivo untreated the has driven immunology. by assay effect This been portal This from earlier, a phenomena inflammatory pre skin the phenotype, to -clinical superior of toxicities of with the X both VYNXXX competitors. inflammatory skin of from the with the to these potential model and the for inhibitory human Slide from demonstrates treatment. diseases with tissue, VYNXXX comparison expected applied I and confirmed perhaps of Interleukin-XX, presents presented
and on healing. model the amounts Now we to of -clinical pre recent relating move the to VYNXXX skin the valuation most
ulcers, intervention commonly patches skin. present mechanisms requires compromised on as blisters the Virus to closure. follow-up repair tissue are and readily healing in skin halt the etiology, rapid of to and innate dermatosis Although lesion This neutrophilic destruction allow facility
an As to not any with these such diseases important assure treatment for as these potential does processes. interfere that
healing daily topical to made of tissue X So, anticipated global [Indiscernible] identical incisions would VYNXXX X% were The that overall The treatment treated composite delay In on on score lesion lesion global vehicle, of date. the of visibility. length, external that model, the healing by anesthesia. demonstrate score study objective known external once lesion a mice width, gel treatment the graph was this this unlike this is was topically comprising degree flank for of It -- left presents and and on lesion our healing would not is confirming therefore side of VYNXXX, impact to either groups score model, either product hairless with healing. the control not Inhibitor perform and killing the that primary the were on lesion ingredient, skin or to alcoholic hydro hydroalcoholic closure VYNXXX closure. similarly lesion vehicle control. VYNXXX active would X.X%, to under time that gel BETi a X swelling, and
As XX.X vehicle repair approximately X% a healing treatment hydroalcoholic score negatively the time VYNXXX mean gel and gel later. hydro X The X%,compared lesion days in of time for appear the was the this skin Elliot alcohol treatment statistically and impact to period. to to the day whereas was does results, remainder continues X.X% for not for VYNXXX X, heal there the Based for to mechanisms. was VYNXXX significant improvement heal upon days mean these
being bed had tissue that lesions of the from Fibrotic healed. study hydro-alcoholic resulted scar. amount result identified fibrotic of frequently in lesion deposits on the tissue in of results of right, treatments graph gel to showed a Looking pure the outcome the treatment this vehicle, a lesion data during a tissue Severity Findings after aesthetic Scale. the at and of in on mass X.X from our moderate the fibrotic the fibrotic Excess the mass period. healing in the the represents formed extent healing end was both assessed
action lower VYNXXX inhibitors. mass BET of a VYNXXX treatment the an at examples animal vehicle. X% presents slide there photograph much with end typical The of fibrotic which was the is anti the is group, in treatment. This of However, fibrotic presence treated of of in comparison, - indicative left tissue mechanism the photography of for
that As lesions The other groups. VYNXXX see, and you visible. an treated distinct evidence less swelling can with of and there of the still residual swelling animal little and is the clearly X.X% flatter central with photograph is are the are residual scars comparison in treatment has
definable treated with conclusion, clearly still animals VYNXXX with reduces the ThXX to and scars with broad satisfied are autoimmune as overall skin of several the mediated inflammatory key validate and very of several we initial present. VYNXXX. attractiveness masks, relevant significant swelling gel significantly this reducing activity data in have right, the scabbing auto-immune have On preliminary hydroalcoholic utility residual of tissue for repair demonstrated In with platform. diseases. dis-regular the we immune And addressing expression generated has earlier improvement outcomes. These belief and diseases, and of fibrotic data serious our in cytokines
on work the With to VYNXXX in XXXX. progresses. to pass to call I generate to program safety into Inhibitor The will We enter non-clinical continue now prerequisite clinic pharmacology program and the We updates enabling is diligently the providing additional [Indiscernible] the intend to and we additional epigenetics. Dave. underway back Dave. BETi data as look forward that,
